Arctic Bioscience - Invitation to presentation of Q3 2026 operational update

Arctic Bioscience will publish its Q3 2026 operational update on Wednesday 11[th] of November 2026, at 07:00 CET.

The same day at 10:00 CET, the Company will host a webcast to present the operational update. Following the presentation, it will be open to questions from the audience.

Webcast details:

Date: Wednesday 11[th] of November 2026

Time: 10:00 CET

Format: Webcast and Q&A

Language: Norwegian/English

The presentation can be accessed with the link below:

https://events.teams.microsoft.com/event/20cb08cb-8215-4f2d-90e7 -17878e8c22a0@ce618813-5158-40b5-b6d0 -2f2cd3f39b20?source=copyLinkLegacyShareLinkDialog

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.